Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142445 | 0.84 | ALDH1A1 (0.47) | KMT2ACCNE1CDK2GSK3BMEN1 | |
| SCHEMBL11323517 | 0.84 | ALDH1A1 (0.47) | KMT2ACCNE1CDK2GSK3BMEN1 | |
| SCHEMBL1279658 | 0.83 | ALDH1A1 (0.46) | KMT2ACCNE1CDK2GSK3BMEN1 | |
| SCHEMBL1491215 | 0.83 | CYP19A1 (0.48) | CYP19A1CYP17A1KMT2AKDM4EMEN1 | |
| SCHEMBL2208957 | 0.82 | MGLL (0.44) | KMT2AKDM4EPOLBMEN1MAPT | |
| SCHEMBL5354116 | 0.82 | NAAA (0.43) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL13065050 | 0.82 | CCNE1 (0.36) | KMT2ACCNE1CDK2GSK3BMEN1 | |
| SCHEMBL18274612 | 0.82 | CCNE1 (0.36) | KMT2ACCNE1CDK2GSK3BMEN1 | |
| SCHEMBL5357731 | 0.82 | NAAA (0.43) | KMT2APOLBCCNE1CDK2GSK3B | |
| SCHEMBL1992162 | 0.82 | MGLL (0.45) | KMT2AKDM4EPOLBMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2491785-A1 | Method and compositions for treating HIV infections | Purdue Research Foundation (US) | 2012-08-29 | — | — | EP | disclosed |
| US-7897635-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897635-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897635-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
| WO-2008133734-A2 | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20070082883-A1 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070082883-A1 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-12 | — | — | US | disclosed |
| US-20070082883-A1 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-12 | — | — | US | disclosed |
| US-7157489-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157489-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157489-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040039016-A1 | HIV protease inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-26 | — | — | US | disclosed |
| WO-2003078438-A1 | CARBAMATES AS HIV PROTEASE INHIBITORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082883-A1 | HIV protease inhibitors | SERPINB1, TMPRSS15, DNPEP | CYP19A1 2748/4885CYP17A1 2021/4885KMT2A 3671/4885 |
| US-20040039016-A1 | HIV protease inhibitors | SERPINB1, TMPRSS15, DNPEP | CYP19A1 2748/4885CYP17A1 2021/4885KMT2A 3671/4885 |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | CYP19A1 1779/4885CYP17A1 590/4885KMT2A 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.